MSCV-BCL6-IRES-GFP Citations (3)

Originally described in: BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 production.
Yu RY, Wang X, Pixley FJ, Yu JJ, Dent AL, Broxmeyer HE, Stanley ER, Ye BH Blood. 2005 Feb 15. 105(4):1777-84. PubMed Journal

---

Articles Citing MSCV-BCL6-IRES-GFP

Articles
BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy. Slone WL, Moses BS, Hare I, Evans R, Piktel D, Gibson LF. Oncotarget. 2016 Apr 26;7(17):23439-53. doi: 10.18632/oncotarget.8273. PubMed
MiR-23~27~24-mediated control of humoral immunity reveals a TOX-driven regulatory circuit in follicular helper T cell differentiation. Wu CJ, Cho S, Huang HY, Lu CH, Russ J, Cruz LO, da Cunha FF, Chen MC, Lin LL, Warner LM, Liao HK, Utzschneider DT, Quon S, Berner J, Camara NOS, Zehn D, Belmonte JCI, Chen LC, Huang SF, Kuo ML, Lu LF. Sci Adv. 2019 Dec 11;5(12):eaaw1715. doi: 10.1126/sciadv.aaw1715. eCollection 2019 Dec. PubMed
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Pighi C, Cheong TC, Compagno M, Patrucco E, Arigoni M, Olivero M, Wang Q, Lopez C, Bernhart SH, Grande BM, Poggio T, Langellotto F, Bonello L, Dall'Olio R, Martinez-Martin S, Molinaro L, Francia di Celle P, Whitfield JR, Soucek L, Voena C, Calogero RA, Morin RD, Staudt LM, Siebert R, Zamo A, Chiarle R. Blood Adv. 2021 Dec 14;5(23):5239-5257. doi: 10.1182/bloodadvances.2021005682. PubMed

If you have published an article using this material, please email us at to have your article added to this page.